BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Instituto Argentino de Diagnóstico y Tratamiento
Buenos Aires, ArgentinaPublications en collaboration avec des chercheurs de Instituto Argentino de Diagnóstico y Tratamiento (1)
2014
-
A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia
British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477